Results 41 to 50 of about 34,959 (356)

Clinical-evolutional particularities of the cryoglobulinemic vasculitis in the case of a patient diagnosed with hepatitis C virus in the predialitic phase [PDF]

, 2018
Hepatitis C virus (HCV) represents a fundamental issue for public health, with long term evolution and the gradual appearance of several complications and associated pathologies.
Boldeanu, Lidia, Boldeanu, Mihail V., Caragea, Daniel C., Ciurea, Marius E., Ciurea, Tudorel, Forțofoiu, Maria, Forțofoiu, Mircea C., Popescu-Drigă, Mircea, Pădureanu, Vlad, Rogoveanu, Ion, Streba, Costin, Săndulescu, Larisa, Vere, Cristin C.   +12 more
core   +3 more sources

Retreatment Options Following HCV Direct-Acting Antiviral Failure [PDF]

Current Treatment Options in Infectious Diseases, 2017
Despite the excellent efficacy of direct acting antivirals (DAA) for hepatitis C virus (HCV), treatment failures do occur. Until recently, retreatment decisions after DAA failure were influenced by the number of available agents, concerns about HCV drug resistance, and lack of data regarding retreatment.
Autumn, Zuckerman, Cody A, Chastain, Susanna, Naggie   +2 more
openaire   +2 more sources

Direct-Acting Antiviral Therapy Outcomes in Canadian Chronic Hepatitis C Telemedicine Patients

Annals of Hepatology, 2017
Introduction: Many of the 300,000 HCV-infected Canadians live in under-served and remote areas without access to HCV healthcare specialists. Telemedicine (TM) and advances in HCV management can facilitate linkage of these marginalized patients to ...
Curtis L. Cooper, Holly Hatashita, Daniel J. Corsi, Parmvir Parmar, Raymond Corrin, Gary Garber   +5 more
doaj   +1 more source

Prevalence of resistance-associated substitutions and phylogenetic analysis of hepatitis C virus infection in Russia

International Journal of Infectious Diseases, 2021
Objectives: Due to limited hepatitis C virus (HCV) sequence availability from patients in Russia, the relationship between subtypes and baseline resistance-associated substitutions (RAS) to direct antiretroviral treatment outcome is not fully understood.
Vasily Isakov, Charlotte Hedskog, Joel O. Wertheim, Reilly E. Hostager, Bandita Parhy, Adriano De Bernardi Schneider, Vithika Suri, Hongmei Mo, Natalia Geivandova, Vyacheslav Morozov, Elena Bessonova, Natalya Gankina, Konstantin Zhdanov, Dzhamal Abdurakhmanov, Evguenia Svarovskaia   +14 more
doaj   +1 more source

Polyclonal and monoclonal B lymphocytes response in HCV-infected patients treated with direct-acting antiviral agents [PDF]

, 2017
Hepatitis C virus (HCV) chronic infection can be associated with extrahepatic manifestations such as mixed cryoglobulinaemia and lymphoproliferative disorders that are endowed with increased rates of morbidity and all-cause mortality.
Burra, Patrizia, Farinati, Fabio, Floreani, Annarosa, Fogar, Paola, Franceschet, Enrica, Gambato, Martina, Nabergoj, Mitja, Pantano, G, Piva, Elisa, Plebani, Mario, Russo, FRANCESCO PAOLO, Schiavinato, Alvise, Tosato, Francesca, Zanetto, Alberto   +13 more
core   +1 more source

Clinician barriers, perceptions, and practices in treating patients with hepatitis C virus and substance use disorder in the United States

Preventive Medicine Reports, 2023
The likelihood of clinicians prescribing direct-acting antiviral (DAA) therapy for patients with chronic hepatitis C virus (HCV) and substance use disorder (SUD) was assessed via a survey emailed throughout the United States to clinicians (physicians and
Haesuk Park, Carolyn Brown, Debbie L. Wilson, Pei-Lin Huang, Pilar Hernández-Con, Patrick Horne, Amie Goodin, Amanda Joseph, Rich Segal, Roniel Cabrera, Robert L. Cook   +10 more
doaj   +1 more source

Hepatitis C virus related cirrhosis decreased as indication to liver transplantation since the introduction of direct-acting antivirals: A single-center study [PDF]

, 2018
AIM: To evaluate waiting list (WL) registration and liver transplantation (LT) rates in patients with hepatitis C virus (HCV)-related cirrhosis since the introduction of direct-acting antivirals (DAAs).
Angeli, Paolo, Burra, Patrizia, Cillo, Umberto, Ferrarese, Alberto, Gambato, Martina, Germani, Giacomo, Russo, Francesco Paolo, Senzolo, Marco, Shalaby, Sarah, Zanetto, Alberto, Zanus, Giacomo   +10 more
core   +1 more source

Variable short duration treatment versus standard treatment, with and without adjunctive ribavirin, for chronic hepatitis C: the STOP-HCV-1 non-inferiority, factorial RCT

Efficacy and Mechanism Evaluation, 2021
Background: High cure rates with licensed durations of therapy for chronic hepatitis C virus suggest that many patients are overtreated. New strategies in individuals who find it challenging to adhere to standard treatment courses could significantly ...
Graham S Cooke, Sarah Pett, Leanne McCabe, Christopher Jones, Richard Gilson, Sumita Verma, Stephen D Ryder, Jane D Collier, Stephen T Barclay, Aftab Ala, Sanjay Bhagani, Mark Nelson, Chin Lye Ch’Ng, Benjamin Stone, Martin Wiselka, Daniel Forton, Stuart McPherson, Rachel Halford, Dung Nguyen, David Smith, M Azim Ansari, Helen Ainscough, Emily Dennis, Fleur Hudson, Eleanor J Barnes, Ann Sarah Walker, the STOP-HCV trial team   +26 more
doaj   +1 more source

Reversion of anergy signatures in clonal CD21low B cells of mixed cryoglobulinemia after clearance of HCV viremia. [PDF]

, 2017
Hepatitis C virus (HCV) causes mixed cryoglobulinemia (MC) by driving clonal expansion of IgM+CD27+ B cells. These cells display both the features of anergy induced by continual engagement of the B cell receptor (BCR), such as high expression of ...
Casato, Milvia, Colantuono, Stefania, DEL PADRE, Martina, Fiorilli, Massimo, Marrapodi, Ramona, Mitrevski, Milica, Todi, Laura, Visentini, Marcella   +7 more
core   +1 more source

Era of direct acting antivirals in chronic hepatitis C: Who will benefit? [PDF]

, 2015
published_or_final_versio
Fung, JYY
core   +1 more source